Vigneri R, Goldfine I D
Diabetes Care. 1987 Jan-Feb;10(1):118-22. doi: 10.2337/diacare.10.1.118.
Metformin, a biguanide antidiabetic agent that can be administered either alone or in combination with sulfonylureas, has been extensively used in Europe and Canada. The mechanism of action of metformin and other biguanides is not completely understood, but recent in vitro and in vivo studies suggest that metformin may act in part by both increasing the binding of insulin to its receptor and potentiating insulin action. Metformin, because of its chemical structure, does not interact with the liver and has a short half-life. Consequently, lactic acidosis, which is a rare complication of metformin, has not been associated with the proper use of this drug. In addition to its antidiabetic actions, metformin causes weight loss in obese diabetic patients and may be useful in managing associated lipid disorders.
二甲双胍是一种双胍类抗糖尿病药物,可单独使用或与磺脲类药物联合使用,在欧洲和加拿大已被广泛应用。二甲双胍及其他双胍类药物的作用机制尚未完全明确,但最近的体外和体内研究表明,二甲双胍的部分作用可能是通过增加胰岛素与其受体的结合以及增强胰岛素作用来实现的。由于其化学结构,二甲双胍不与肝脏相互作用,且半衰期较短。因此,乳酸酸中毒这种二甲双胍罕见的并发症与该药物的合理使用并无关联。除了抗糖尿病作用外,二甲双胍还能使肥胖糖尿病患者体重减轻,可能有助于治疗相关的脂质紊乱。